Keywords: clinical decision support systems, data mining, artificial intelligence, chronic hepatitis, prostate cancer, biopsy

Abstract: Clinical Decision Support Systems (CDSS) have the potential to replace painful, invasive, and costly procedures, to optimize medical decisions, improve medical care, and reduce costs. An even better strategy is to make use of a knowledge discovery in data approach, with the aid of artificial intelligence tools. This results in transforming conventional CDSS in Intelligent Clinical Decision Support (i-CDSS). Evolving i-CDSS give to the conventional CDSS the capability of self-modifying their rules set, through supervised learning from patients data. Intelligent and evolving CDSS represent a strong foundation for evidence-based medicine. We proposed a methodology of building i-CDSS and related concepts. These are illustrated with some of our results in liver diseases and prostate cancer, some of them showing the best published performance.

1 INTRODUCTION AND BACKGROUND

The use of information technology for replacing painful, invasive, and/or costly procedures, for optimizing various medical decisions, or for improving medical care and reducing the costs, represent major goals of Medical Informatics. Implementing Clinical Decision Support Systems (CDSS) (Berner, 2007) on a large scale is a major step toward these goals. Using a knowledge discovery in data approach with artificial intelligence tools, one can build Intelligent Clinical Decision Support Systems (i-CDSS) instead of conventional CDSS.

We performed a set of investigations on constructing i-CDSS for several liver diseases, prostate and thyroid cancer, and chromosomal disorders (e.g., Down syndrome) during pregnancy. The high performance of the liver and prostate i-CDSS determined us to consider some of these methods and concepts mature and general enough to be presented, but still under development. Here, we present a methodology of building i-CDSS and the related concepts. These are illustrated with some of our results in liver and prostate diseases, showing the best published performances out to date, to our knowledge.

Chronic Hepatitis B and C are major diseases of mankind and a serious global public health problem. The persons with these chronic diseases are at high risk of death from cirrhosis and liver cancer. Liver biopsy is the gold standard for grading the severity of disease, and staging the degree of fibrosis, and the grade of necroinflammation. The most used scoring systems are:

1. META VIR A (A stands for activity) or Ishak NI (NI stands for necroinflammatory) for necroinflammatory grade
2. META VIR F or Ishak F for the fibrosis stage (F stands for fibrosis).

By assigning scores for severity, grading, and staging of hepatitis, they are very important for patient management.

Liver biopsy is invasive, painful, and relatively costly; complications severe enough to require hospitalization can occur in about 4% of patients (Lindor, 1996). In a review of over 68,000 patients recovering from liver biopsy, 96% experienced adverse symptoms during the first 24 hours of recovery. Hemorrhage was the most common symptom, but infections also occurred. Side effects of the biopsies included pain, tenderness, internal bleeding, pneumoth-
orax, and rarely, death (Tobkes and Nord, 1995)

There are two main non-invasive diagnosis techniques of interest (Shaheen et al., 2007). FibroScan is a type of ultrasound machine that uses transient elastography to measure liver stiffness. The device reports a value that is measured in kilopascals (kPa). FibroTest for assessing fibrosis, and ActiTest for assessing necroinflammatory activity are available through BioPredictive (www.biopredictive.com). These tests use algorithms to combine the results of serum tests of beta 2-macroglobulin, haptoglobulin, apolipoprotein A1, total bilirubin, gamma glutamyltranspeptidase (GGT), and alanine aminotransferase (ALT).

The results of these diagnosis techniques are not directly interpretable by a pathologist, but can be extrapolated to a fibrosis and necroinflammation score. FibroTest and FibroScan have reasonably good utility for the identification of cirrhosis, but lesser accuracy for earlier stages. It is considered that refinements are necessary before these tests can replace liver biopsy (Shaheen et al., 2007).

We used a knowledge discovery in data, based on artificial intelligence, to investigate the possibilities of accuracy improvements and of expressing the results in the pathologist scoring systems.

In our prostate cancer studies, one goal was to investigate the possibility of developing a non-invasive diagnosis i-CDSS, based mainly on the concentrations of a set of 8 angiogenic molecules in serum. A detailed description of these data can be found in (Balacescu et al., 2008). For the purpose of this paper, which is to outline the methodology and the concepts related to evolving intelligent CDSS, unnecessary molecular biology, medical and data mining technicalities were eliminated.

To our knowledge, this is the first study, integrating angiogenic molecules, clinical and laboratory data, to develop intelligent systems capable to predict various results of the biopsy, e.g., liver fibrosis or prostate cancer diagnosis, with an acceptable accuracy. The meaning of acceptable accuracy depends on the specific medical context and is a matter of consensus. Probably, in this context the prediction accuracy should be at least 80%.

Because the results of the liver, prostate, or other organs biopsy, are used in many important medical decisions, in the management of the related diseases, we investigated the possibility of developing other i-CDSS, starting from these. For example, important treatment decision are partially based on biopsy.

Chronic hepatitis B and C are treated with drugs called Interferon or Lamivudine, which can help some patients. This treatment decision is based on several patients selection criteria. For example, the criteria for selecting the patients with chronic hepatitis C who will benefit from Interferon treatment, are:

1. Chronic infection with hepatitis C virus (HCV): antibodies against HCV (anti-HCV) are present for at least 3 months.
   (a) the hepatitis B surface antigen (HBsAg) is present for at least 6 months, or
   (b) the hepatitis B e antigen (HBeAg) is present for at least 10 weeks.

2. The cytolytic syndrome: the transaminases level is increased or normal.

3. Pathology (biopsy): the Ishak NI $\geq 4$ and Ishak F $\leq 3$.

4. The virus is replicating: the transaminases level is increased or normal, and anti-HCV are present, and RNA-HCV $\geq 10^5$ copies/milliliter.

For hepatitis B there is a similar set of selection rules.

Analyzing these treatment decisions, one can identify two problems:

1. Invasiveness: the patients selection criteria include fibrosis and necroinflammation assessed by liver biopsy, an invasive medical procedure.

2. Cost of the wrong decisions: patients selection errors are very costly, because Interferon or Lamivudine therapy costs thousands of dollars.

In the methodological context proposed in this paper, developing solutions to these problems is straightforward. The aforementioned conditions are easy to implement in an interactive computer program and biopsy could be replaced by the non-invasive i-Biopsy. Developing intelligent CDSS, based on non-invasive medical investigations, and optimized selection criteria, could be of great benefit to the patients and could also save money.

2 DEVELOPING INTELLIGENT CLINICAL DECISION SUPPORT: A METHODOLOGY AND RELATED CONCEPTS

In essence, we extracted and integrated information from various non-invasive data sources, e.g. imaging, clinical, routine laboratory or molecular data, and build i-CDSS capable to predict various results of the biopsy, e.g., liver fibrosis or prostate cancer diagnosis, with an acceptable accuracy. The meaning of acceptable accuracy depends on the specific medical context and is a matter of consensus. Probably, in this context the prediction accuracy should be at least 80%.

Because the results of the liver, prostate, or other organs biopsy, are used in many important medical decisions, in the management of the related diseases, we investigated the possibility of developing other i-CDSS, starting from these. For example, important treatment decision are partially based on biopsy.

Chronic hepatitis B and C are treated with drugs called Interferon or Lamivudine, which can help some patients. This treatment decision is based on several patients selection criteria. For example, the criteria for selecting the patients with chronic hepatitis C who will benefit from Interferon treatment, are:

1. Chronic infection with hepatitis C virus (HCV): antibodies against HCV (anti-HCV) are present for at least 3 months.
   (a) the hepatitis B surface antigen (HBsAg) is present for at least 6 months, or
   (b) the hepatitis B e antigen (HBeAg) is present for at least 10 weeks.

2. The cytolytic syndrome: the transaminases level is increased or normal.

3. Pathology (biopsy): the Ishak NI $\geq 4$ and Ishak F $\leq 3$.

4. The virus is replicating: the transaminases level is increased or normal, and anti-HCV are present, and RNA-HCV $\geq 10^5$ copies/milliliter.

For hepatitis B there is a similar set of selection rules.

Analyzing these treatment decisions, one can identify two problems:

1. Invasiveness: the patients selection criteria include fibrosis and necroinflammation assessed by liver biopsy, an invasive medical procedure.

2. Cost of the wrong decisions: patients selection errors are very costly, because Interferon or Lamivudine therapy costs thousands of dollars.

In the methodological context proposed in this paper, developing solutions to these problems is straightforward. The aforementioned conditions are easy to implement in an interactive computer program and biopsy could be replaced by the non-invasive i-Biopsy. Developing intelligent CDSS, based on non-invasive medical investigations, and optimized selection criteria, could be of great benefit to the patients and could also save money.
More precisely, one should investigate if it is possible:

1. To build i-CDSS capable to predict the biopsy results—fibrosis stage and necroinflammation grade—with an accuracy of at least 80%.

2. To integrate the i-CDSS predicting the biopsy results with the other selection criteria in an i-CDSS for Interferon treatment.

3. To make the Interferon treatment i-CDSS an evolving one, capable to optimize the treatment decisions by self-modifying through learning.

It is interesting to note that some of the components of the treatment i-CDSS are fixed in time, while other can evolve, by learning from data. In this example, the i-Biopsy component is fixed, being an input-output relationship, already discovered from patients data, and used to predict the results of the biopsy, without performing it. The component implementing the treatment selection criteria could be either fixed or evolving through learning. In the first case we have a fixed i-CDSS, and in the second case an evolving one.

Evolving i-CDSS can minimize the costs due to erroneous patients selection, and maximize the benefit of the treatment. They can optimize the selection rule sets by finding the relevant selection criteria and their proper cutoff values. For this, the outcomes of the Interferon treatment must be clearly defined as numerical or categorical attributes and registered in a data base for each treated patient.

Then, intelligent agents are employed to learn the prediction of the treatment outcomes. They must be capable of expressing the extracted information as rules, using non-invasive clinical, laboratory and imaging attributes as inputs. Using feature selection (see for example (Guyon et al., 2006)) one will find the relevant patient selection criteria.

Thus, the i-CDSS started with the accepted patients selection criteria, but these are evolving. It is worth to mention that the evolved selection criteria could be different, from those initially proposed by physicians, and usually better. However, they should be always evaluated by the experts. In the supervised learning process, intelligent agents also discover the proper cutoff values of the relevant selection criteria. Again, these are usually better than those proposed by experts, but they should always be evaluated by them. In our opinion, evolving through learning from patients data is crucial for evidence based-medicine.

These i-CDSS are the result of a data mining predictive modeling strategy, which is now patent pending, consisting mainly in:

1. Extracting and integration information from various medical data sources, after a laborious pre-processing:
   (a) cleaning features and patients,
   (b) various treating of missing data,
   (c) ranking features,
   (d) selecting features,
   (e) balancing data.

2. Testing various classifiers or predictive modeling algorithms.


For modeling, we tested the prediction accuracy of various types of artificial intelligence agents:

1. Neural Networks of various types and architectures,
2. Decision trees C5.0 and Classification and Regression Trees
3. Support Vector Machines, with various kernels
4. Bayesian Networks
5. Genetic Programming based agents.

i-Biopsy is an intelligent system based on any algorithm or combination of algorithms capable of learning from data. Of course, accuracy is very important but physicians also prefer white-box algorithms and transparent decisions.

We have chosen C5.0 decision trees, the last version of the C4.5 algorithm (Quinlan, 1993), with 10-fold cross-validation. As ensemble method, we used Freund and Schapire’s boosting (Freund and Schapire, 1997) for improving the predictive power of C5.0 classifier learning systems. A set of C5.0 classifiers is produced and combined by voting, and by adjusting the weights of training cases. We suggest that boosting should always be tried when peak predictive accuracy is required, especially when unboosted classifiers are already quite accurate.

Genetic programming was another important choice, giving accurate and transparent i-CDSS in the form of mathematical models of the input-output relationship (manuscript in preparation). Transparency of the i-CDSS is affected by boosting and is less useful when the number of variables is large.

3 MAIN RESULTS

In what follows, some of the results illustrating the practical and conceptual significance of i-Biopsy are presented. The examples are i-CDSS selected from gastroenterology and urology.
In one of our hepatological studies, we collected a dataset of 700 chronic hepatitis C patients and about 135 inputs. One of the i-CDSS has liver fibrosis as the predicted output expressed as Metavir F score, having five classes: from Metavir F0 to Metavir F4. The accuracy of the first experiments was about 60%. Pre-processing increased the accuracy with 20% to 25%. As we mentioned, we tested various algorithms and settings, but C5.0 accuracy was one of the highest, about 80% (see Table 1 and Table 2 for some examples).

Table 1: Results of experiments for feature and algorithm selection for METAVIR F0 prediction, formulated as a one-versus-all classification (Logistic Regres stands for Logistic Regression; AUC stands for Area Under the Curve).

<table>
<thead>
<tr>
<th>Model</th>
<th>Accuracy%</th>
<th>Features</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>C5</td>
<td>99.639</td>
<td>19</td>
<td>1</td>
</tr>
<tr>
<td>CART</td>
<td>95.307</td>
<td>17</td>
<td>0.755</td>
</tr>
<tr>
<td>Logistic Regres</td>
<td>93.863</td>
<td>25</td>
<td>0.918</td>
</tr>
<tr>
<td>Neural Net</td>
<td>92.78</td>
<td>25</td>
<td>0.648</td>
</tr>
</tbody>
</table>

Parameter tuning and boosting increase the accuracy of some i-CDSS even to 100% (Floares et al., 2008; Floares, 2009b).

We also developed liver i-Biopsy versions based on Bayesian Networks and on Genetic Programming, some of them as binary classifiers (work in progress). After many experiments, we conclude that important is to reach the highest robust accuracy, between 80% and 100%, and the test for this is the external validation.

Because the results of the biopsy are central to important medical decisions, in the management of chronic hepatitis patients, it was relatively easy to build i-CDSS for Interferon treatment (Floares, 2008), (Floares, 2009a). This was done just by adding the aforementioned patients selection criteria to the i-Biopsy. This non-invasive i-CDSS is of a special kind; being able to evolve, by attempting to predict the progressively accumulating outcomes of the Interferon treatment, it will eventually identify the proper patients selection criteria, and their cutoff values from data (see section 2 for more details). Thus, the rules set of this i-CDSS is evolving.

We tried to develop not only the technical aspects of the intelligent CDSS, evolving through learning from data, but also the related concepts.

i-Biopsy, one of the central concepts, is an intelligent system (the prefix “i-” coming from intelligent), supporting important medical decisions, by being capable to predict, with an acceptable accuracy, the results usually given by a pathologist, examining the tissue samples from biopsies. Real biopsy is performed on different organs, e.g., liver, prostate, etc., and the pathologists expressed their findings as diagnoses or scores of a largely accepted scoring system. While the concept is general, individual systems must be specific (see below).

For example, let us shortly analyze liver (organ) i-Biopsy (the intelligent counterpart of the real biopsy), in chronic hepatitis C (disease), assessing liver fibrosis (diagnose), expressed by METAVIR F (pathologist scoring system). This liver i-Biopsy takes as inputs and integrate various routine, non-invasive, clinical, imaging and lab data.

To distinguish between the scores of the real biopsy and their counterparts predicted by i-Biopsy, we proposed the general terms of i-scores. There are many examples, like Gleason score in prostate cancer, but we continue to focus on the gastroenterological applications, where we have:

1. The liver i-Biopsy is the i-CDSS corresponding to the real liver biopsy; the i-META VIR F scores are the values predicted by i-Biopsy for the META VIR-F fibrosis scores, designating exactly the same pathological features.
2. The i-META VIR F scores and the biopsy META VIR F scores could have different values for the same patient, at the same moment, depending for example on the prediction accuracy or pathologist errors.
3. i-META VIR F scores are obtained in a non-invasive, painless, and riskless manner, as opposed to META VIR-F scores, assessed by liver biopsy.

For simplicity, we referred only to the META VIR F scores, but these considerations are general, and can be easily extrapolated to other liver scores, like Ishak F, META VIR A, and Ishak NI. Moreover, these conceptual clarifications apply to any situation in which the following elements are present:

1. an anatomical structure, e.g., liver, or prostate, etc.
2. the invasive procedure, e.g., biopsy
3. a disease, e.g., chronic hepatitis C or B, prostate cancer or benign prostatic hyperplasia
4. a set of pathological features or diagnoses to assess, e.g., fibrosis, necroinflammation, etc.

5. a set of classes for the pathological findings, e.g., Gleason or META VIR scores, pathological diagnoses, etc.

The second element (biopsy) could be replaced, at least in a considerable percentage of cases, by the i-Biopsy, and the fifth element by the i-scores.

We have built the following i-CDSS which can be used for Interferon treatment decision support:

1. Module for liver fibrosis prediction,
   (a) according to META VIR F scoring system, with and without liver stiffness (FibroScan),
   (b) according to Ishak F scoring system, with and without liver stiffness (FibroScan).

2. Module for the grade of necroinflammation (activity) prediction, according to Ishak NI scoring systems.

Also, we developed some prostate i-Biopsy systems, as non-invasive i-CDSS counterparts for some prostate biopsy results. For example, i-Gleason score is the i-Biopsy predicted Gleason score (work in progress), and is also central to many important medical decisions in prostate cancer. The three classes classifiers, distinguishing between normal, benignant and malignant are more interesting for the fundamental research. The binary classifiers, especially those distinguishing between malignant and benignant, are clinically oriented. The preliminary results are very encouraging, with accuracy ranging from 97.8% to 100%.

4 DISCUSSION

A short digression about the meaning of the diagnosis accuracy, of the i-CDSS in general and i-Biopsy in particular, seems necessary, because it confused many physicians, especially when reporting very high values like 100%. Many physicians believe that 100% accuracy is not possible in medicine. The meanings will be made clear trough examples. Typically, an invasive liver (or prostate, etc.) biopsy is performed to the patient, and a pathologist analyzes the tissue samples assessing fibrosis, necroinflammation, etc., and expressed the results as scores or pathological diagnosis. The pathologist may have access to other patient medical data, but usually these are not necessary for him or her to formulate the pathological diagnosis. Moreover, in some studies it is required that the pathologist knows nothing about the patient. His or her diagnosis can be more or less correct or even wrong, for many reasons not discussed here. We have proposed i-CDSS predicting the fibrosis scores resulted from liver biopsy, or the prostate cancer diagnosis resulted from prostate biopsy, with accuracy reaching 90% - 100%. For the i-CDSS, several clinical, imaging, and lab data of the patient are essential, because they were somehow incorporated in the system. They were used like input features to train the system, and they are required for a new, unseen patient, because i-Biopsy is a relationship between these inputs and the fibrosis, necroinflammation scores, or diagnosis as outputs. The category of i-CDSSs discussed here do not deal directly with diagnosis correctness, but with diagnosis prediction accuracy. Without going into details, this is due in part to the supervised nature of the learning methods used to build them. The intelligent agents learned to predict the results of the biopsy given by the pathologist, and the pathologist diagnosis could be more or less correct. For example, let us suppose that the pathologist diagnosis is wrong. The i-Biopsy could still be 100% accurate in predicting this wrong diagnosis, but this is rarely the case. In other words, the i-Biopsy will predict, in a non-invasive and painless way, and without the risks of the biopsy, a diagnosis which could be even 100% identical with the pathologist diagnosis, if the biopsy is performed. While the accuracy and the correctness of the diagnosis are related in a subtle way, they are different matters. i-Biopsy will use the information content of several non-invasive investigations, to predict the pathologist diagnosis, without performing the biopsy. The correctness of the diagnosis is a different matter, but typically a good accuracy correlates well with a correct diagnoses. The accuracy of the diagnosis, as well as other performance measures like the area under the receiver operating characteristic (AUROC), for a binary classifier system (Fawcett, 2004), are useful for intelligent systems comparison. To our knowledge, the proposed liver i-Biopsy system outperformed the most popular and accurate system, FibroTest and ActiTest (Shaheen et al., 2007) commercialized by BioPredictive company, and FibroScan. The liver i-Biopsy is a multi-classes classifier, expressing the results in the pathologist’s scoring systems, e.g., five classes for META VIR F and seven classes for Ishak F. Multi-classes classifiers are more difficult to develop than binary classifiers, with outputs not directly related to the fibrosis scores. We also build binary classifiers as decision trees with similar accuracy and mathematical models (work in progress). Despite the fact that AUROC is only for binary classifiers, loosely speaking a 100% accuracy n classes classifier is equivalent
with n binary classifiers with AUROC = 1 (maximal). BioPredictive company analyzed a total of 30 studies (Poynard et al., 2007) which pooled 6,378 subjects with both FibroTest and biopsy (3,501 chronic hepatitis C). The mean standardized AUROC was 0.85 (0.82-0.87). The robustness of these results is clearly demonstrated by this cross-validation, while i-Biopsy results need to be cross-validated. The fact that i-Biopsy, in its actual setting, relies on routine ultrasound features is both a strong point and a weak one, because of the subjectiveness in ultrasound images interpretation. It is worth to note that in certain circumstances the result of the liver i-Biopsy could be superior to that of real biopsy. When building the i-CDSS, the results of the potentially erroneous biopsies, which are not fulfilling some technical requirements, were eliminated from the data set. Thus, the i-Biopsy predicted results correspond only to the results of the correctly performed biopsies, while a number of the real biopsy results are wrong, because they were not correctly performed. Due to the invasive and unpleasant nature of the biopsy, it is very improbable that a patient will accept a technically incorrect biopsy to be repeated. Unlike real biopsy, i-Biopsy can be used to evaluate fibrosis evolution, which is of interest in various biomedical and pharmaceutical studies, because, being non-invasive, painless and without any risk, can be repeated as many time as needed.

Also, in the early stages of liver diseases, often the symptoms are not really harmful for the patient, but the treatment is more effective than in more advanced fibrosis stages. The physician will hesitate to indicate an invasive, painful and risky liver biopsy, and the patients are not as worried about their disease as they are about the pain of the biopsy. However, i-Biopsy can be performed and an early start of the treatment could be much more effective.

ACKNOWLEDGEMENTS

We thank to the following medical teams: Dr. Monica Lupors, Dr. T. Suteu and Prof. Dr. R. Badea, from Medical Imaging Department, Dr. H. Stefanescu and Dr. Z. Sparchez, from Hepatology Department, Dr. A. Serban from Pathology Department, Dr. N. Crisan, Dr. B. Feciche and Prof. Dr. I. Coman, from Urology Department, University of Medicine and Pharmacy Cluj-Napoca, Romania, Dr. Carmen Floares, Dr. O. Balcescu, Dr. Ioana Neagoe Dr. Loredana Balacescu, Dr. Oana Tudoran, and Prof. Dr. A. Irimie, from Cancer Institute Cluj-Napoca, Romania. We also thank to the computer science team: Dr. F. Manolache, E. Suica, and T. Popa.

REFERENCES


Floares, A. G. (2009a). Intelligent clinical decision supports for interferon treatment in chronic hepatitis c based on i-biopsy. In International Joint Conference on Neural Networks, 2009, Atlanta, Georgia, USA.


